Pivotal Therapeutics (PVTTF) 0.1800 $PVTTF
Pivotal Therapeutics grants incentive stock options
PR Newswire - Tue Apr 08, 1:58PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2013. Options to acquire a total of 4,176,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN(R) Commercialization
PR Newswire Europe - Tue Mar 04, 8:44AM CST
WOODBRIDGE, Ontario, March 4, 2014 /PRNewswire/ --
Pivotal Therapeutics closes financing; receives over CDN $7.7 million to further VASCAZEN® commercialization
CNW Group - Tue Mar 04, 7:00AM CST
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total proceeds of CDN $7,743,580. Pivotal experienced greater demand than anticipated for the Financing and as a result was oversubscribed by 2,744 units resulting in an increase of $2,743,580 over the CDN $5,000,000 previously announced. The financing was led by Crossover Healthcare Fund, LLC, and included Broadfin Capital, LLC and Porter Capital Management Co.
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA
HA Formulation
PR Newswire Europe - Wed Jan 29, 12:08PM CST
WOODBRIDGE, Ontario, January 29, 2014 /PRNewswire/ --
IIROC Trade Resumption - PVO
CNW Group - Wed Jan 29, 11:04AM CST
Trading resumes in:
IIROC Trading Halt - PVO (all issues)
CNW Group - Wed Jan 29, 10:45AM CST
The following issues have been halted by IIROC:
Pivotal Therapeutics Announces Third Quarter 2013 Financial Results
CNW Group - Fri Nov 29, 3:38PM CST
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies announced its third quarter financial results and operational highlights for the three and nine months ended September 30, 2013.
Pivotal Therapeutics Inc. Announces Extension of Debt Financing
CNW Group - Fri Nov 01, 8:02PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it has extended the closing date of the previously announced (October 2, 2013 and October 7, 2013) debt financing to November 30(th), 2013.
John P. Nicholson Jr., MD, MBA, FACC Appointed to Pivotal Board of Directors
CNW Group - Wed Oct 30, 4:45PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that John P. Nicholson Jr., MD, MBA, FACC has been appointed to the Company's Board of Directors.
Pivotal Therapeutics grants incentive stock options
PR Newswire - Tue Apr 08, 1:58PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2013. Options to acquire a total of 4,176,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN(R) Commercialization
PR Newswire Europe - Tue Mar 04, 8:44AM CST
WOODBRIDGE, Ontario, March 4, 2014 /PRNewswire/ --
Pivotal Therapeutics closes financing; receives over CDN $7.7 million to further VASCAZEN® commercialization
CNW Group - Tue Mar 04, 7:00AM CST
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total proceeds of CDN $7,743,580. Pivotal experienced greater demand than anticipated for the Financing and as a result was oversubscribed by 2,744 units resulting in an increase of $2,743,580 over the CDN $5,000,000 previously announced. The financing was led by Crossover Healthcare Fund, LLC, and included Broadfin Capital, LLC and Porter Capital Management Co.
Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA
HA Formulation PR Newswire Europe - Wed Jan 29, 12:08PM CST
WOODBRIDGE, Ontario, January 29, 2014 /PRNewswire/ --
IIROC Trade Resumption - PVO
CNW Group - Wed Jan 29, 11:04AM CST
Trading resumes in:
IIROC Trading Halt - PVO (all issues)
CNW Group - Wed Jan 29, 10:45AM CST
The following issues have been halted by IIROC:
Pivotal Therapeutics Announces Third Quarter 2013 Financial Results
CNW Group - Fri Nov 29, 3:38PM CST
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies announced its third quarter financial results and operational highlights for the three and nine months ended September 30, 2013.
Pivotal Therapeutics Inc. Announces Extension of Debt Financing
CNW Group - Fri Nov 01, 8:02PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it has extended the closing date of the previously announced (October 2, 2013 and October 7, 2013) debt financing to November 30(th), 2013.
John P. Nicholson Jr., MD, MBA, FACC Appointed to Pivotal Board of Directors
CNW Group - Wed Oct 30, 4:45PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that John P. Nicholson Jr., MD, MBA, FACC has been appointed to the Company's Board of Directors.
